No Data
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
Bicycle Therapeutics Plc (NASDAQ:BCYC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
No Data
No Data